详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

出处：

DOI：

ISSN：

关键词： Idiopathic pulmonary fibrosis (IPF) Lung cancer (LC) Pathogenesis Treatment

摘要：

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with chronic progressive fibrosis of unknown etiology; it is characterized by persistent fibrosis of the lungs accompanied by irreversible lung function decline and high mortality rates. A large body of evidence suggests a significant association between IPF and lung cancer (LC). IPF itself increases the risk of LC development, and LC associated with IPF often originates in areas of honeycomb lesions in IPF. In addition, there are similarities between the two diseases in terms of genetics as well as cellular molecular mechanisms; examples include genetic and epigenetic variants, fibroblast activation and proliferation, epithelial‒mesenchymal transition (EMT), abnormal mechanical forces generated in the lungs, and aberrant signaling pathway activation, which may drive the progression of pathology in both diseases. In this review, we describe in detail the epidemiological and clinical associations of LC in patients with IPF, highlight recent studies on the shared pathogenesis between IPF and LC, and discuss current advances in the treatment of LC associated with idiopathic pulmonary fibrosis.© 2025. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区医学

小类 | 2 区呼吸系统

最新[2025]版：

大类 | 2 区医学

小类 | 2 区呼吸系统

第一作者：

第一作者机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]An update on Becker's nevus: Pathogenesis and treatment [2]Pathogenesis and treatment of multiple myeloma. [3]Regulated cell death in cancer: from pathogenesis to treatment [4]Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer [5]肿瘤性发热的发病机制及诊治进展 [6]Application of a Module of the MD Anderson Symptom Inventory in Chinese Patient after Lung Cancer Surgery (MDASI-LC) [7]Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective [8]EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs) [9]Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer [10]Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead